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ASSOCIATIONS BETWEEN IRRITABLE BOWEL SYNDROME AND POST 
TRAUMATIC STRESS DISORDER AMONG VETERAN POPULATIONS 
ABISHEK AROKIADOSS 
ABSTRACT 
Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder 
(FGID) characterized by recurrent abdominal pain and change in bowel habits and is highly 
associated with depression and anxiety. IBS is estimated to affect about 5-20% of the global 
population2,29. However, little data exist regarding the association of IBS in patients with 
Post Traumatic Stress Disorder (PTSD). Therefore, we investigated the Veterans’ After-
discharge Longitudinal Registry (VALOR) cohort of combat-exposed veterans with and 
without PTSD for comorbid IBS, functional dyspepsia (FD), and Gastroesophageal Reflux 
Disease (GERD). 
Methods: Medical records of veterans enrolled in the VALOR project (N=1649) with 
(N=1028) and without PTSD (N=619) were examined for the presence of IBS, FD, and 
GERD based on ICD coding at time points T1 (baseline) and T4 (average follow up 4.7 
years). Male and female veterans were recruited into the study at a ratio of 1:1. IBS 
diagnosis was made using ICD 9/10 coding and PTSD diagnosis was made using the PTSD 
module of the Structured Clinical Interview for 
DSM-IV. Statistical analyses of data were performed using Chi-square test, T-test, and 
logistic regression analyses. 
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Results: Baseline demographics of veterans with PTSD and control subjects were similar. 
IBS and FD were present in VALOR subjects with (3.9%, 1.2%, respectively) and without 
PTSD (3.4%, 0.8%) in similar frequencies (p=0.6 and p=0.48, respectively) at baseline 
whereas GERD without esophagitis is significantly more frequent in the PTSD group 
relative to the No PTSD group (14.8%, 10.3%, respectively; p=0.01). Over the course of 
the study the diagnosis of IBS, and other related FGID, decreased from T1 to T4. The only 
diagnosis that did change significantly was an increase in GERD with esophagitis. At T1, 
the only diagnosis that was more common in veterans with PTSD compared to veterans 
without PTSD was GERD without esophagitis. At both T1 and T4 the severity of PTSD 
did not predict a diagnosis of most FGID including IBS, GERD with esophagitis, or 
functional dyspepsia. However, rates of GERD without esophagitis were positively 
correlated with severity of PTSD symptoms. At T1 veterans with re-experiencing 
symptoms of PTSD were more likely to have IBS. However, at T4 veterans with avoidance 
symptoms of PTSD were more likely to have IBS, while veterans with re-experiencing 
symptoms, negative changes in mood of cognition, and those experiencing hyperarousal 
were more likely to have GERD without esophagitis.     
 Conclusions: Prior studies have shown that combat-exposed veterans were at risk for 
IBS, however we report PTSD in combat-exposed veterans did not incur a risk for the 
association with IBS or FD but did so for GERD, specifically PTSD in combat exposed 
veterans did incur a risk for the association GERD without esophagitis and was positively 
correlated to the severity of PTSD symptoms. Specific subgroups of PTSD symptoms 
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were also found to correlate with specific diagnoses. Specifically, the re-experiencing 
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Within veteran populations nearly 20% to 30% are diagnosed with Post Traumatic 
Stress Disorder (PTSD)27, with many of these same veterans having various 
comorbidities ranging from 40% to 60% of veterans having 3 or more psychiatric 
disorders. The most common comorbidities for veterans to have alongside PTSD are 
major depressive disorder, mania, and dysthymia3. It is also known that Irritable Bowel 
Syndrome (IBS) is very common amongst veteran populations36. Among veterans, those 
with IBS are more likely to present with one or more psychiatric comorbidities including 
depression and anxiety27. Whereas the association between IBS and disorders like 
depression have been studied in some depth, the association of IBS and PTSD however 
represent a significant knowledge gap. Connections such as traumas suffered and 
stressors that induce symptoms are similar between IBS and PTSD25. Pathophysiological 
pathways such as the Hypothalamic-Pituitary-Adrenal (HPA) axis and changes in Central 
Nervous System (CNS) processing are altered in both IBS and PTSD. This study aims to 
identify significant associations between IBS and PTSD in a well-established prospective 
longitudinal study of combat exposed veterans.      
A. Irritable Bowel Syndrome  
About 5-20% of the global population suffers from IBS. IBS is a functional 
gastrointestinal disorder (FGID) characterized by abdominal pain upon defecation, and a 
change in quality or quantity of defecation at least once a week for at least the past three 
months, with symptoms first showing at least six months prior to diagonsis7,2,29. Any 
symptoms showing cannot be caused by an underlying gastrointestinal disorder for a 
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positive diagnosis of IBS to occur. FGID’s are a common gastroenterological diagnosis 
that is commonly associated with motility disturbances, visceral hypersensitivity, 
alterations to the mucosal layer, alterations in immune system functions, and alterations 
between communication of the central nervous system and the enteric nervous system 
and are mainly defined as disorders arising from problems of the gut brain axis7. There 
are four subtypes of IBS depending on the predominant stool consistency. IBS with 
diarrhea (IBS-D) is associated with more than a quarter of bowel movements are watery. 
IBS with constipation (IBS-C) is associated more than quarter of bowel movements are 
hard lumps with bouts of constipation. Diarrhea can occur in patients with IBS-C, but at 
minimum one quarter of disordered bowel movements have hard lumps or be associated 
with straining to be considered IBS-C. IBS of mixed type (IBS-M) is a combination of 
either constipation and diarrhea, with more than a quarter of bowel movements are hard 
and pebbly and also more than a quarter are watery. On average patients with IBS-M note 
having bouts of constipations and bouts of diarrhea at around equal frequency. 
Unclassified IBS is defined as bowel movements that do not have the same abnormalities 
in stool consistency to be grouped into the other three subgroups. Patients with 
unclassified IBS have the other IBS-defining symptoms including abdominal pain and 
disordered bowel/ abnormal bowel movements, without any clear pattern of either 
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Table 1: IBS Symptom by Subtype 
Table Legend: Diagnosable symptoms of IBS based on bowel movements over a 3-




IBS-D Abdominal pain or abdominal discomfort once a week for at least three 
months upon defecation; Diarrhea at least once a week for 3 months  
IBS-C Abdominal pain or abdominal discomfort once a week for at least three 
months upon defecation; Constipation followed by stools that are hard and 
pebbly at least once a week for 3 months  
IBS-M Abdominal pain or abdominal discomfort once a week for at least three 
months upon defecation; At least one quarter of defecation is either lose 
and at least one quarter of defecation is hard and pebbly 
IBS-U Abdominal pain or abdominal discomfort once a week for at least three 
months upon defecation: Frequent changes in defecation patterns that do 
not fit the previous three subtypes 
 
There are several underlying pathophysiological etiologies of IBS: disturbance of 
the gut microbiome, changes to the HPA Axis, motility disturbances, visceral 
hypersensitivity, altered mucosal and immune function, altered central nervous system 
(CNS) processing, and biopsychosocial conceptualization7,2,11.  
Changes in the intestinal microbiome have been theorized to have a role in 
IBS23,26. Even though there has been no general signature gut microbiome identified for 
IBS, the most common bacterial phyla of the human gut microbiome in healthy subjects 
are Bacteroidetes and Firmicutes1. The relative abundance of different bacterial species 
can be changed not only in subjects with IBS but was also observed with the subtype and 
severity of IBS symptoms as well31. For instance, one study examined different IBS 
subtypes with respect to different population of gut microbes. This was achieved by 
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collecting stool samples from 195 subjects between the ages of 18-65. All patients were 
diagnosed with IBS according to the standards set forth in ROME III, and samples were 
collected on average 26 days apart. DNA was extracted from fecal samples using 
quantitative polymerase chain reaction targeting for order of bacteria 
Methanobacteriales31. This study suggested that in patients with IBS-C the relative 
abundance of Clostridiales is much greater, while patients with IBS- D and IBS-M have a 
higher relative abundance of Bacteroides. Instances of major changes of the bacterial 
composition of the intestine, such as after a round of antibiotics, can – usually 
temporarily- produce symptoms of IBS. Fecal samples from IBS patients show an altered 
composition of the gut microbiome, with lactate-producing and lactose-metabolizing 
bacteria in higher percentages when compared to healthy patients31.  
Changes to the HPA axis leads to an increased release of glucocorticosteroids. 
This increase leads to an increase of catecholamines and increases the responsiveness of 
adrenergic receptors which increases reactive oxygen species. An increase of reactive 
oxygen species leads to inflammation of the intestine and causes a change in the 
homeostasis of the mucosa, which leads to an increased bacterial translocation into the 
mucosa leading to some symptoms seen in IBS32.  
Motility disturbances can also lead to the symptoms associated with IBS. 
Alterations to motility of the intestine can lead to nausea, diarrhea, or acute abdominal 
pain, all of which are common symptoms of IBS5. These alterations to intestinal motility 
can be induced by strong emotional stress, which is a common feature of many patients 
with IBS5. The abdominal pain associated with IBS could be explained by visceral 
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hypersensitivity. If the sensitivity of the intestine is increased the pain threshold will be 
lowered. In patients with IBS with predominant constipation the constant distension of 
the intestine leads to visceral hypersensitivity, which in turn may result in abdominal pain 
sensation from intestinal distension alone5. Changes in the permeability of the mucosal 
membrane can also be observed in IBS. If the mucosa of the intestines becomes more 
permeable it can increase the migration of mast cells and cause a release of inflammatory 
cytokines. This can lead to visceral hypersensitivity, which can lead to pain as discussed 
earlier.  
Changes in CNS processing can also be observed in patients with IBS. Increased 
activation of the HPA axis can lead to an increased rate of secretion of cortisol, which 
can lead to decreased visceral sensitivity and increased intestinal motility. As discussed 
earlier, increased intestinal motility can lead to nausea, diarrhea, or acute abdominal 
pain5.  
Biopsychosocial factors can also affect symptoms and manifestation of IBS. 
Certain IBS symptoms like diarrhea or bloating may be under or over-reported in certain 
countries and cultures, which would affect how IBS is diagnosed5. Differences in how 
symptoms like bloating and abdominal pain are defined from culture to culture can cause 
many people to be underdiagnosed with IBS. How different cultures relate to stress can 
also affect the manifestation of IBS symptoms2. Studies have shown that when rural 
populations move to more urban centers rates of IBS increase dramatically compared to 
their rural counterparts2. In aggregate, several studies from around the world have shown 
that women are at slightly higher risk to develop IBS compared to men2. Rates of IBS 
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also decrease slightly with age with the biggest shift being between patients above the 
age of 50 versus below the age of 50, with patients under 50 being more likely to develop 
IBS2.  
There are also many psychiatric disorders that are comorbid with IBS. Panic 
disorders are a common comorbidity for IBS, with a lifetime prevalence rate of 25-40%, 
whereby specific panic disorders like agoraphobia have a prevalence rate as high as 
20%10. This high prevalence rate is hypothesized to be influenced by dysregulation of the 
HPA axis that is found in both IBS and panic disorders. The low threshold for stress-
induced outcomes observed in these patients can exacerbate the symptoms of both 
disorders. Generalized anxiety disorder is another psychiatric morbidity that is commonly 
associated with IBS with prevalence rates as high as 30%. Anxiety caused by generalized 
anxiety disorders has been hypothesized to increase visceral hypersensitivity which is 
thought to worsen the symptoms of IBS10.Specifically, anxiety and fear surrounding 
symptoms related to IBS may worsen IBS symptoms. Studies have also shown that 
selective serotonin reuptake inhibitors can treat the symptoms of both IBS and 
generalized anxiety disorders. These medications could help patients with IBS by 
stimulating serotonin receptors in the gastrointestinal track and increase gastric motility, 
which could help with constipation symptoms of IBS10. The most commonly diagnosed 
psychiatric comorbidity with IBS is major depressive disorder and is estimated to have a 
prevalence rate of 30-50%. It has also been shown that female patients with IBS are more 
likely to develop major depressive episodes. This is hypothesized to be caused by an 
increased rate of tryptophan degradation that is seen in female IBS patients. Tryptophan 
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degradation can lead to a depletion of serotonin supplies in the body, which could lead to 
major depressive episodes10. Several studies have also shown that IBS is associated with 
PTSD, but previous studies have not shown any specific connections between the two 
disorders. Previous studies have shown that 36% of IBS patients have met the lifetime 
diagnostic criteria for PTSD. Treatment of PTSD in patients may also help to improve 
IBS symptoms10. 
 
B. Post-Traumatic Stress Disorder 
PTSD is a psychiatric disorder in which people who have been exposed to a 
traumatic experience then experience a series of symptoms as a result of that trauma and 
these symptoms manifest usually 3 months after a traumatic event but can manifest years 
after the event20. These symptoms fall into one of four categories: intrusion/ re-
experiencing, avoidance, negative cognition/ mood, or hyper-arousal. Intrusion/re-
experiencing can take the form of recurrent or intrusive thoughts, distressing dreams of 
traumatic experience, flashbacks, and strong emotional and physical reactions to anything 
that reminds the patient of the traumatic experience. Avoidance symptoms manifest as 
actively avoiding thoughts, feelings, or anything related to traumatic events. Symptoms 
of negative cognition manifest as: amnesia surrounding the event, continued negative 
state, inability to feel positive emotions, and feelings of detachment. Hyper-arousal 
symptoms manifest as: anxiety, difficulty sleeping, reduced concentration, increased 
irritability, and increased bouts of anger. Patients need to show at least one of the 
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symptoms in response to a traumatic trigger from a certain sub-type to be diagnosed with 
PTSD.  
Overall, in the US the prevalence of PTSD is estimated about 8%, with women 
being more likely to develop PTSD compared to men at about 20.4% for women 
compared to 8% for men20. In the USA the three groups with higher prevalence of PTSD 
are: African Americans (14-16%), Native Americans (14-16%), and refuges from conflict 
zones (9-60%)20.  
 
 
Table 2: PTSD Symptoms by Subtype   
Table Legend: Symptoms for various PTSD subtypes, at least one of the symptoms is 
needed in response to a traumatic trigger for a positive diagnosis with a specific subtype. 
PTSD Symptom 
Subtype 
Symptoms (At least one is needed) 
Intrusion/ Re-
experiencing  
• Recurrent or intrusive thoughts 
• Distressing dreams of traumatic experience  
• Flashbacks 
• Strong emotional or physical reactions to events 
reminiscent of traumatic event  
Avoidance  • Actively avoiding thoughts, feelings, or anything 
related to the traumatic events 
Negative Cognition/ 
Mood 
• Amnesia surrounding the event 
• Continued negative state 
• Inability to feel positive emotions 
• Feelings of detachment 
Hyper-Arousal • Anxiety 
• Difficulty sleeping 
• Reduced concentration 
• Increased irritability  
• Increased bouts of aggression 
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A variety of experiences are associated with PTSD and could include but are not 
limited: combat, assault, rape, natural disasters, loss of a loved one, or a medical 
emergency. PTSD is thought to be caused by an inability of the person to stop a 
behavioral response to an external stimulus that is similar to the trauma experienced by 
the person, which lead to maladaptive cognitive strategies to then deal with the stress and 
fear associated with the trauma. There are a variety of factors pre trauma, during the 
trauma, and post trauma that could modulate the severity of PTSD symptoms. Pre-trauma 
factors such as poor socio-economic status or a previous psychiatric disorder can make 
dealing with trauma, like developing healthy coping mechanisms, more difficult. The 
severity, intensity, and duration of a traumatic experience can also modulate the 
symptoms of PTSD. Post trauma life stressors or the lack of a social support system can 
modulate the severity of PTSD20. Because of the importance of fear in the development 
of PTSD the amygdala is vital in its development. The amygdala is a pair of almond 
shaped structures made up of several nuclei, groups of nerves, found within each 
hemisphere of the brain and is involved in process of experiencing emotions.  
Researchers have found that a reduced size of the amygdala is an important factor 
for the risk whether a person will develop PTSD20. Researchers have also found that 
changes in the hypothalamic-pituitary axis are a marker for whether a person is at a 
greater risk for developing PTSD, but the actual changes that put a person at a higher risk 
have not been reliably documented20. The diagnosis of PTSD is achieved first through a 
physical examination to rule out any physical medical conditions that could lead to 
symptoms seen. A psychological evaluation is then performed to document possible 
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symptoms. Documented symptoms are then compared to accepted symptoms for a 
positive diagnosis of PTSD. The current clinical management of PTSD includes 
psychotherapy in combination with exposure therapy and Cognitive Behavioral Therapy 
(CBT). Exposure therapy is used by therapists to help patients become desensitized to 
traumatic experiences and help control their reaction to emotional stimuli, while CBT is 
used to help patients challenge maladaptive mental processes that induce PTSD 
symptoms20.  
There are several systems theorized to be involved in the underlying 
pathophysiology of PTSD: the noradrenergic system, serotonergic receptors, and the 
HPA axis17,6,33. Changes to the noradrenergic system caused by ongoing stress can lead to 
increases to noradrenaline in synapses in cortical regions of the brain. The dysregulation 
of noradrenaline in the synapse is caused by a decrease of norepinephrine transporters 
(NET), which helps remove noradrenaline from the synapse. This increase in 
noradrenaline can lead to depressive or anxious symptoms17.  
Some PTSD patients have been found to have a decrease in serotonin receptors. 
Serotonin has been linked to fear regulation, and excess of serotonin can induce flashback 
like symptoms similar to those in PTSD. The 5-HT1A receptors are found predominantly 
in the raphe, hippocampal formation, hypothalamus, and the prefrontal cortices, and help 
reduce serotonin release. Neuropathological disorders that cause a reduction in cortex 
volume or reduction in synapse proteins also lead to a reduction of 5-HT1A receptors and 
could lead to an increase of anxiety and fear like that seen in PTSD33. High levels of 
    
 
11
corticotropin releasing factors released at the time of a traumatic event may be tied to 
encoding of the traumatic memory and an increased response of the HPA axis. 
There are also several other psychiatric disorders that are comorbid with PTSD. 
One study gathered data 7403 individuals between the ages of 16-64 to analyze rates of 
common psychiatric disorders and what percentage were comorbid with PTSD. The data 
was collected over the course of two interviews with the first interview collecting 
demographic data, and the second including a series of interviews and questionnaires to 
diagnose various psychiatric disorders. The study found 213 people who met the criteria 
for PTSD (75 men, 138 women). Of these 213 subjects more than three quarters of 
patients interviewed (78.5%) met the criteria for at least one other psychiatric disorder as 
compared to only 14.5% of patients who did not have PTSD39.  This study determined 
that most common psychiatric disorders patients comorbid with PTSD included 
depressive mood disorders (16-54%), followed by social phobias (36%), obsessive 
compulsive disorder (28%), and generalized anxiety disorder (10%)39. PTSD was 
hypothesized to worsen the symptoms for depression and generalized anxiety disorder or 
even be factor in developing these disorders in the first place39.  
C. Functional Dyspepsia 
Functional Dyspepsia (FD) is another very common FGID found in the general 
population including veteran populations. FD is characterized by a variety of symptoms 
including feeling too full after consuming a meal, feeling full early on in a meal, a 
burning sensation in the upper abdomen and esophagus, and pain in the upper abdomen8. 
To be diagnosed with FD patients but have at least one of the symptoms continuously for 
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three months, and the first instance of the symptoms must have occurred at least six 
months before diagnosis8. The patient can also only be diagnosed with FD if any of the 
above symptoms cannot be explained by any other underlying condition. FD has a 
prevalence of approximately 25% in western countries and 15% in Asian countries8, with 
an overall incidence rate of about 5% over a 10-year period. FD id frequently comorbid 
with IBS with some studies showing the comorbidity rate to be approximately 10-27% in 
certain populations8. There are two recognized subtypes for FD, epigastric pain syndrome 
and post-prandial distress syndrome. Patients who complain of feeling too full after meals 
or feel full early into a meal alongside the other common symptoms of FD are diagnosed 
with the post-prandial distress syndrome subtype. This feeling of discomfort after or 
during a meal must occur at least three times a week for a positive diagnosis of this 
subtype8. Diagnosis of the epigastric pain syndrome subtype usually presents with a 
burning sensation in the epigastric region caused by reflux at least once a week severe 
enough to disrupt daily activities. Diagnosis for FD is first approached by reviewing a 
patient’s history for potential warning symptoms, like constant abdominal bloating or 
discomfort or more alarming symptoms like weight loss. To rule out other causes for FD 
like symptoms physical palpation of the esophageal region or an upper endoscopy may be 
used to rule out underlying factors. If no underlying factors are identified to explain FD 
like symptoms the patient is then diagnosed with FD8. There are several risk factors 
believed to increase developing FD, including gastrointestinal infections, use of non-
steroidal anti-inflammatory drugs, childhood abuse, childhood environmental microbial 
exposure, and even psychosocial status8.  
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Table 3: Functional Dyspepsia Symptoms by Subtype   
Table Legend: Symptoms for Functional Dyspepsia and subtype, at least one of the 
symptoms is needed for three months regularly for a positive diagnosis with a specific 
subtype. 
Subtype Symptoms 
Functional Dyspepsia • Feeling too full soon into a meal 
or feeling too full after a meal 
•  epigastric pain or burning 
•  Having on or more symptoms 
regularly for three months with 
first onset at least six months prior  
Epigastric Pain Syndrome • At least one of the symptoms of 
FD 
• Epigastric pain that causes 
disruptions to daily living at least 
once a week for three months 
Post-Prandial Distress Syndrome • At least one symptom of FD 
• Feeling too full Feeling too full 
soon into a meal or feeling too full 
after a meal 
• Discomfort or pain sever enough 
to cause disruptions to daily living 
at least three times a month for at 
least three months 
 
There are several mechanisms hypothesized that are associated with FD 
including: changes in function to gastric motility, bacterial infections, and disturbances in 
communication between the central nervous system and enteric nervous system8. 
Changes to gastric motility, specifically delays in gastric emptying can explain the 
symptoms experienced by patients with FD. Delayed gastric emptying in FD is seen in 
between meals in which the movement of gastrointestinal track is abnormal or even 
retrograde, which can cause a backup of digested food taking longer to empty. Delayed 
gastric emptying can lead to visceral hypersensitivity of the stomach which can lead to 
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feelings of pain when the stomach is full7,8. Bacterial infections, specifically H. Pylori 
can lead to the abdominal burning experienced by some FD patients. H. Pylori infections 
can lead to a weakening of the epithelial wall of the stomach leading to increased 
inflammation of the stomach wall by exposure to proinflammatory cytokines. Increased 
proinflammatory cytokines can lead to the burning feeling felt by FD patients, and could 
lead to increased excitation of the enteric nervous system8. The final theory of FD 
symptom induction is disturbances in communication between the central nervous system 
and enteric nervous system. Inflammation of the stomach wall either through bacterial 
infections or some other means can not only cause the local gut wall to become more 
sensitive, but it can also cause dorsal horn neurons (in the spinal cord) to become 
hypersensitive. This can lead to these neurons to send pain signals for normal gastric 
functions like distension or emptying leading to pain after eating8. Emotional states 
caused by psychiatric disorders, like depression or anxiety, are hypothesized to also 
worsen this problem. Anxiety is thought to heighten the problems caused by 
hypersensitivity which could lead to discomfort or pain when the stomach or intestines 
become slightly distended during or after a meal8. 
 
D. Gastroesophageal Reflux Diseases 
Gastroesophageal Reflux Disease (GERD) is a highly prevalent gastrointestinal 
disease in which contents from the stomach regurgitates into the esophagus. GERD is 
characterized by either heartburn or regurgitation into the upper throat, both of which are 
accompanied by a burning or painful feeling in the chest area, but primarily affects the 
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lower esophageal sphincter22. Symptoms occurring outside of the esophagus 
(extraesophageal manifestations), mainly pain in the larynx, is not uncommon and is 
associated with constant throat clearing. This is caused by acid reflux entering the larynx 
causing the pain and hoarseness. Other extra-esophageal regions for symptom 
manifestation are feeling like a lump is in the back of the throat, which is thought to be 
caused by excessive reflux affecting the upper esophageal sphincter4. GERD is one the 
most common causes for chest pain that are not cardiac in nature. The prevalence of 
GERD is estimated to be at around 20% in adults in North America19. There are also 
several symptoms that are a rare but can be cause for alarm. These symptoms include 
difficulty or pain upon swallowing, anemia, and weight loss4.    
 
Table 4: Gastroesophageal Reflux Disease Symptoms with Common Complication   
Table Legend: Symptoms for Gastroesophageal Reflux Disease Symptoms with 
Common Complication, at least one of the symptoms is needed with either a round of 




• Heartburn or regurgitation 
• Pain or burning feeling in the upper chest 
• Pain in the larynx 
• Constant throat clearing and hoarseness 
• Lump in the back of the throat 
• Difficulty or pain upon swallowing 
• Anemia 
• Weight Loss 
GERD with 
Esophagitis 
• Above symptoms 
• Erosion and damage to the esophagus 
• Narrowing of the esophagus 
• Upper GI bleed 
• Peptic stricture 
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There are many factors that lead to GERD that include: relaxation of the lower 
esophageal sphincter, inadequate acid clearance, reduced mucosal protection, decreased 
saliva production, and increased abdominal pressure19,4. All of these factors then can lead 
to increased acid reflux into the lower esophagus leading to heartburn and feelings 
burning. If acid reflux is not treated properly then damage to the esophagus and larynx 
can occur. 
There are many demographic risk factors that increase the chances for developing 
GERD, including age, high body mass index, smoking, anxiety, and depression. 
Diagnosis of GERD is accomplished clinically by determining the presence of typical 
symptoms (reflux and regurgitation) and observing how GERD-related symptoms can be 
resolved by common acid suppression medications. If patients have symptoms that are in 
line with a GERD diagnosis, they are given medications such as Histamine Type 2 
Receptor blockers or proton pump inhibitors that are effective in reducing gastric acid 
secretion. If patients experience resolution of symptoms subsequent to this 
pharmacological treatment a diagnosis of GERD considered confirmed19,4. If symptoms 
of GERD do not stop with treatment an upper gastrointestinal endoscopy may be needed 
to confirm a positive GERD diagnosis. This is used to see if damage caused by reflux is 
present in the esophagus and can also help identify GERD-related complications early as 
well. If patients present with typical GERD symptoms and with the above-mentioned 
alarm symptoms an upper endoscopy is indicated to evaluate the patient for the presence 
of complications like Barrett’s esophagus, a chronic intestinal metaplasia state of the 
distal esophageal mucosa carrying an increased risk for esophageal adenocarcinoma. If 
    
 
17
GERD is not treated properly a secondary diagnosis, called erosive esophagitis, is 
common. Esophagitis is caused by erosion and damage to the esophagus from reflux that 
can lead to a narrowing of the esophagus, upper GI bleed, and a peptic stricture4.       
E. Known Connections Between IBS and PTSD 
 There has been some evidence in the past that suggested an association between 
IBS and PTSD. One of the significant overlaps is the shared pathophysiology, whereby 
both IBS and PTSD are associated with dysregulation of the HPA axis. For PTSD, the 
HPA axis has been implemented in many symptoms of PTSD. The HPA axis is involved 
in the encoding of traumatic memories, and its dysregulation can lead to increased fear 
and stress response common in many symptoms of PTSD. The HPA axis has also been 
implemented playing a role in IBS via increased inflammation of the intestine leading to 
hypersensitivity of the intestinal wall which can lead to intestinal pain. Dysregulation of 
this axis can lead to increased release of serotonin. Which as discussed earlier can also 
lead to increased intestinal motility, a common symptom of IBS. The serotonergic system 
is affected in both PTSD and IBS. There is evidence that a reduction in either serotonin 
production or serotonin receptors leads to the symptoms found in PTSD, a decrease in 
serotonin or the serotonergic system is theorized to increase feelings of fear or anxiety. 
Serotonin is also a vital signaling molecule in the gastrointestinal tract, and a reduction in 
serotonin has been shown to decrease gut motility which can lead to constipation. There 
are also many symptoms or comorbidities that are common to both IBS and PTSD. Both 
PTSD and IBS have spikes in cortisol that take longer to return to baseline compared to 
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normal patients. It has also been found that approximately 36% of IBS patients have 
PTSD as a comorbidity10.  
 
Table 5: Overlap in Shared Systems, Traumas, and Comorbidities Between IBS and 
PTSD   
Table Legend: IBS and PTSD have several similarities in systems affects, common 
traumas experienced, and comorbidities developed my patients. 
Connection Similarities  
System Dysregulation • HPA Axis 
• Serotonergic System 
• Cortisol release 
Shared Traumas • Sexual Assault 
• Domestic Violence 
• Natural Disaster 
Common Comorbidities  • Depression  
• Anxiety 
• Panic Disorders 
 
Many IBS patients also have similar trauma events found in PTSD. 40% of IBS 
patients were sexually abused by a family member, 22% of patients were victims of 
domestic violence, and 17% of patients have lived through a natural disaster. PTSD has 
also been found to be the most common psychological comorbidity for IBS, with patients 
with IBS their risks of developing PTSD are three times more likely compared to 
baseline18. Amongst veteran populations one meta-analysis analyzed eight research 
studies searching for the key words: abuse, childhood abuse, PTSD, and IBS. They 
compiled the rates of PTSD and IBS to determine whether shared trauma made 
developing either PTSD or IBS more likely. The study concluded that patients with 
PTSD were almost three times more likely to develop symptoms of IBS later on25. In one 
UK based study 6427 participants were given 2 questionnaires on average three years 
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apart. Both questionaries recorded similar information and was meant to act as a follow 
up. The questionnaires measured rates of diarrhea and vomiting, IBS, and symptoms of 
PTSD. It was shown that some veteran populations did not have IBS when returning from 
service but were more likely to have recorded instance of vomiting or diarrhea. 
Furthermore, veterans that had either diarrhea or vomiting were more likely to eventually 
develop symptoms of IBS after deployment15. In another study 339 African American 
women veterans were given a series of self-administered questionaries regarding IBS, 
quality of life with IBS, depression, anxiety, and PTSD. Participants were then separated 
based on a positive IBS diagnosis. The study found that amongst female veterans, 
participants with PTSD were more likely to also have IBS. In the study 51% of veterans 
with IBS also had PTSD, as opposed to only 30.9% of veterans only having PTSD16. 
Another US based study recruited 337 women veterans between the ages of 18 to 70. The 
participants were administered a questionaries to record severity of symptoms for bowel 
related disorders, PTSD, and trauma. The study found 113 of the participants met the 
requirements for IBS. The most common form of trauma faced by the participants, sexual 
assault, was also more common in the group with IBS compared to the non-IBS group. 
The study concluded that participants who experienced a traumatic event, like assault or 
combat, were more likely to develop IBS, and that a positive diagnosis of depression or 








We hypothesized that diagnosis of either IBS or PTSD will increase the likelihood 
of a diagnosis of the other based on the observation of the shared underlying 
pathophysiological components of IBS and PTSD. The first specific aim of this study was 
to determine the prevalence of IBS, FD, and GERD, and associated demographic data 
within the large prospective Veterans After-discharge Longitudinal Registry (VALOR) 
cohort. The second specific aim was to use various appropriate statistical methods to test 
whether IBS, FD, and GERD are more likely associated with PTSD subjects as compared 































Study population and procedure 
 For the study, the Veterans After-discharge Longitudinal Registry (Project 
VALOR) was used, which has a total enrollment of 1649 patients. All participants in the 
cohort were deployed to combat areas and were given at least one mental health 
assessment between July 2008 and December 2009, these mental health assessments were 
all made at a Veterans Health Administration facility. Participants sampled for PTSD 
were based on diagnosis made by previous medical care professionals and were chosen at 
a ratio of 3:1 participant with PTSD (N=1028) to participants without PTSD (N=619). 
Women veterans were oversampled to ensure a 1:1 ratio of male to female participants. 
Initially 4,391 patients were identified for the study, but only 1649 participants consented 
and completed the initial assessment. There were 2 missing subjects in this study 
population. The initial assessment (T1) was made up of a series of questionnaires and 
interviews that were given between the years of 2009 to 2012. The study conducted a 
total of 4 assessments, with the final assessments (T4) being administered between 2015 
to 2017. The average time between T1 and T4 for participants was on average 4.64 years, 
with a standard deviation of 0.5 years. Participants consented to researchers accessing 
their record throughout the timeline of the registry. Procedures were approved by the 
Institutional Review Board at Veterans Affair Boston Healthcare System and the Human 
Resource Protection Office of the U.S. Army Medical Research and Materiel 
Command28.     
 




 The Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition 
(DSM-IV) was used at T1 to assess trauma and PTSD status because data collection for 
the VALOR cohort was done before Diagnostic and Statistical Manual of Mental 
Disorders-Fifth Edition (DSM-V) was published. To assess for PTSD status two different 
tests were administered at T1 and T4. At T1 the Structured Clinical Interview for DSM-
IV11 (SCID-IV) was used to assess PTSD status. At T4 the Structured Clinical Interview 
for DSM-V10 (SCID-V) was used to assess for PTSD status. At both T1 and T4 
assessments were administered over the phone via trained doctoral-level assessors. At T1 
symptom severity for PTSD was measured using the PTSD Checklist, Civilian version28 
(PCL-C). At T4 PTSD symptom severity was assessed using the PCL-527. The PCL-C 
and PCL-5 are 17-item and 20-item, respectively, self-report measures of PTSD symptom 
severity for the past month.  
At both T1 and T4 the Prime-MD Patient Health Questionnaire (PHQ) was 
administered to participants to assess for other psychiatric comorbidities23. The PHQ is a 
26-item questionnaire that screens for a variety of psychiatric disorders including: 
unipolar depressive disorder, panic disorder, somatoform disorder, and generalized 
anxiety disorder. At T1 self-reporting was used to collect demographic data including 
marital status, education, and household income. Other demographic data like smoking 
status and body mass index (BMI), and comorbidity conditions, were extracted at a later 
date directly from participant medical records.  
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Gastrointestinal disorders like IBS, FD, and GERD were identified 6 months prior 
to T1 and T4 from participant medical records using inpatient and outpatient 
administrative data. For the presence of gastrointestinal disorders 6 months before and 
after T1 we used ICD-9 codes: IBS (564.1); FD (536.8); and GERD (530.81). For T4, we 
used ICD-10 codes: IBS (K58.0, K58.1, K58.2); FD (K30); and GERD (K21). 
Statistical Analyses 
To analyze the proportion of patients with both PTSD and a gastrointestinal 
disorder Chi-square tests and Fisher’s Exact tests were conducted. The gastrointestinal 
disorders used for these tests were IBS, FD, and GERD. Chi-square tests and Fisher’s 
Exact tests were also used to examine the frequency of IBS with psychiatric 
comorbidities such as depression, Generalized Anxiety Disorder, panic disorder, and 
somatization. To test whether the SCID PTSD diagnostic status predicted gastrointestinal 
diseases at T1 and at T4 logistic regression was used. Logistic regression was also used to 
determine whether PTSD symptom severity predicted certain gastrointestinal 
comorbidities at T1 or at T4. Finally, logistic regression was used to determine whether 
specific PTSD symptom subgroups help predict a diagnosis of certain gastrointestinal 








 Overall, for the entire VALOR cohort there 1028 patients diagnosed with PTSD, 
and 619 that were not. 49% of patients with PTSD were male, while 48% of patients 
without PTSD were male. The majority of participants both in the PTSD and no PTSD 
group were married (50% vs 41%), and the highest educational level attained by both 
groups was some college, with the VALOR cohort at 35% and IBS patients at 31%. A 
majority of participants in both groups were white, at 78% and 76.3% respectively. Most 
demographic characteristics were not different between PTSD and No PTSD subjects. 
PTSD subjects were slightly older (38 years) than No PTSD control subjects (36.6 years; 
p< 0.01) and had a slightly smaller proportion of Whites than No PTSD subjects (75% vs 
81%; p<0.01). Within the VALOR cohort 1647 patients were recruited, of those at the 
beginning of the study (T1): 1028 were diagnosed with PTSD (63%), 61 were diagnosed 
with IBS (4%), 17 were diagnosed with functional dyspepsia (1%), 221 were diagnosed 









    
 
25
Table 6: Demographic Data for VALOR Cohort Participants 
Table Legend: VALOR (Veterans’ After-discharge Longitudinal Registry) is a 
longitudinal prospective registry of 1649 combat-exposed veterans with and without 
PTSD from Operation Enduring Freedom and Operation Iraqi Freedom.  Overall, 
demographic data of subjects at baseline with PTSD (N=1028) and without PTSD 
(N=619) are similar. P values were calculated using two-sided t test and Chi Square test. 
SD denotes Missing data are: All (N=2), Educational Level (N=7), Marital status (N=2), 
and Race (N=49).  





(N=619) P Value 
Male; N (%)  824 (49) 528 (51) 296 (48) 0.16 
Age (yr+SD) 
 









140 (9) 84 (8.2) 56 (9.0) 0.55 
Divorced 334 (20) 233 (22.7) 101 (16.3) 0.002 
Widowed 11 (0.7) 5 (0.5) 6 (1.0) 0.23 







Other 46 (3) 26 (2.5) 20 (3.2) 0.42 
High School 165 (10) 113 (10.1) 52 (8.4) 0.08 
Vocational 
School 
67 (4) 43 (4.2) 24 (3.9) 0.74 
Some 
College 
576 (35) 365 (35.7) 209 (33.8) 0.41 
Associates 
Degree 
263 (16) 168 (16.5) 95 (15.3) 0.55 
Bachelor's 
Degree 
395 (24) 233 (22.8) 162 (26.2) 0.12 
Master’s 
Degree 






10 (0.6) 8 (0.8) 2 (0.3) 0.25 
American 
Indian 
18 (1.1) 15 (1.5) 3 (0.5) 0.07 
Asian 15 (1) 8 (0.8) 7 (1.2) 0.48 
Pacific 
Islander 
4 (0.2) 3 (0.3) 1 (0.2) 0.62 
Black 261 (16) 179 (18.0) 82 (13.6) 0.02 
White 1240 (78) 750 (75.3) 488 (81.1) <0.01 
Multiracial 62 (4) 41 (4.1) 21 (3.5) 0.55 
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Table 7: Demographic Data for VALOR Cohort PTSD Participants with IBS and without 
IBS 
Table Legend: This VALOR (Veterans’ After-discharge Longitudinal Registry) sample 
represents combat-exposed veterans with PTSD (N=1028) from Operation Enduring 
Freedom and Operation Iraqi Freedom.  No differences of demographic data of subjects 
at baseline with IBS (N=40) and without IBS (N=988) are noted except a higher 
proportion of females in the IBS group (72%; p =0.002). P values were calculated using 
two-sided t test and Chi Square test. SD denotes Standard Deviation. Missing data are: 
Educational Level (N=7), Marital status (N=2), and Race (N=32) 
  IBS: YES  
(N=40) 
 IBS: NO  
(N=988) 
P Value 




 39 ± 9.8 
(25 – 60) 
38 ± 9.7 










5 (12.8) 79 (8) 0.27 
Divorced 11 (28.2) 222 (22.5) 0.42 
Widowed - 5 (0.5) 0.69 
Single 5 (13) 162 (16) 0.55 







High School 4 (10.3) 109 (11) 0.84 
Vocational 
School 
1 (2.6) 42 (4.3) 0.62 
Some College 12 (30.8) 353 (35.9) 0.48 
Associates 
Degree 
7 (17.9) 161 (16.4) 0.76 
Bachelor’s 
Degree 
13 (33.3) 220 (22.4) 0.11 
Master’s 
Degree 
2 (5.1) 89 (9.1) 0.42 
Doctoral 
Degree 




Race N (%) 
American 
Indian 
1 (3) 14 (1.5) 0.55 
Asian - 8 (0.8) 0.55 
Pacific 
Islander 
- 3 (0.3) 0.76 
Black 8 (21.2) 171 (18) 0.62 
White 29 (76.3) 721 (75.3) 0.92 
Asian - 41 (4.3) 0.19 
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The VALOR cohort was composed of 78% and 76.3% white in the general group 
and IBS group and 16% and 21.2% African American for the same groups. Compared to 
other studies exploring either IBS or PTSD there are generally more Caucasians included 
than African Americans. In White et al. a study that was investigating trauma exposure 
for women veterans, the racial makeup was 38.8% for Caucasian to 34% for African 
Americans36. Similarly in the study by Graham et al., which also examined female 
veterans and how IBS affected their quality of life the study’s participant population was 
at 39.9% Caucasian and 48.2% African American, a higher percentage compared to the 
VALOR cohort16. But the study Qassem et al., which was exploring common 
comorbidities for PTSD, the ratio of Caucasian to African American was similar to the 
VALOR cohort at 92% Caucasian and 2.5% African American39. Looking at other 
demographic data the mean age for the general VALOR cohort was 37.5 ± 9.9 years and 
39± 9.8 years for participants with both IBS and PTSD, this is slightly younger on 
average than other studies. White et al had subjects enrolled with an average age of 49 
years, Graham et al. had an average age of 48.5 years for the participants in the study, 
and Qassem et al. had an average age of 51.3 years for the participants in the study16, 36, 
39. The average attained education level for the VALOR cohort was slightly less 
compared to other studies. The majority of participants in the VALOR cohort attended 
some college (35%; p=0.41), while a majority of participants with both IBS and PTSD 
earned a bachelor’s degree (33.3%). In Graham et al. 57.7% of participants in the study 
attended some college. In Goodwin et al. 54.6% of participants completed A rank or 
completed some university.      
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Cross tabulation of the cohort demographics at T1 show that: 40 patients have 
both IBS and PTSD (2%), 12 patients have both functional dyspepsia and PTSD (0.7%), 
and 157 patients have both GERD and PTSD (9.5%). At T1 GERD without esophagitis 
was more likely to be associated with PTSD, p=0.010, followed by GERD with 
esophagitis, p=0.082. At T1 IBS was least likely to be associated with PTSD, p= 0.604   
 
Table 8: Cross Tabulations of gastrointestinal comorbidities with PTSD at Beginning of 
Study 
Table Legend: Cross Tabulations of gastrointestinal comorbidities with PTSD at 
beginning of VALOR Cohort study (T1). The 4 common gastrointestinal comorbidities 
were selected to determine which was most likely to be associated with a diagnosis of 
PTSD. Results shown in tables show how many participants had PTSD with a 
gastrointestinal comorbidity. No means a participant did not have the corresponding 
diagnosis, while Yes means a participant has a corresponding diagnosis. P-value was 






No Yes Total 
No 598 21 619 
Yes 988 40 1028 
Total 1586 61 1647 
p-value: 0.604 
 





No Yes Total 
No 614 5 619 
Yes 1016 12 1028 
Total 1630 17 1647 
p-value: 0.484 









No Yes Total 
No 555 64 619 
Yes 876 152 1028 
Total 1431 216 1647 
p-value: 0.010 
 





No Yes Total 
No 555 64 619 
Yes 876 152 1028 
Total 1642 5 1647 
p-value: 0.082 
 
Later on, in the study, at T4: 1028 patients were diagnosed with PTSD (63%), 42 
patients were diagnosed with IBS (2.5%), 1 patient was diagnosed with functional 
dyspepsia, and 178 patients were diagnosed with GERD (11%). Cross tabulation of the 
cohort demographics at T4 show that: 27 patients have both IBS and PTSD (2%), 1 
patient has both functional dyspepsia and PTSD, and 124 patients have both GERD and 
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Table 9: Cross Tabulations of gastrointestinal comorbidities with PTSD at T4  
Table Legend: Cross Tabulations of gastrointestinal comorbidities with PTSD at end of 
VALOR Cohort study (T4). The 4 common gastrointestinal comorbidities were selected 
to determine which was most likely to be associated with a diagnosis of PTSD. Results 
shown in tables show how many participants had PTSD with a gastrointestinal 
comorbidity. No means a participant did not have the corresponding diagnosis, while Yes 
means a participant has a corresponding diagnosis. P-values were calculated using 







No Yes Total 
No 604 15 619 
Yes 1001 27 1028 
Total 1605 42 1647 
p-value: 0.144 
 





No Yes Total 
No 619 1 620 
Yes 1027 1 1028 
Total 1646 1 1647 
p-value: 0.403 
 





No Yes Total 
No 572 47 619 
Yes 915 113 1028 
Total 1487 160 1647 
p-value: 0.001 









No Yes Total 
No 612 7 619 
Yes 1017 11 1028 




Over the course of the study from T1 to T4 the instances of gastrointestinal 
diseases studied decreased. The VALOR cohort was further subdivided based on racial 
status, marital status, gender, and educational groups, and also by IBS and PTSD 
diagnosis. Analyzing first the frequencies of IBS, functional dyspepsia, and GERD in 
PTSD subjects, only GERD was more likely to be associated with PTSD between T1 and 
T4 for the cohort. Both IBS and FD had similar rates with (3.9%, 1.2%, p=0.6) and 
without PTSD (3.4%, 0.8%, p=0.48), while GERD was at 14% in the PTSD group 
compared to 10.3% in the control No PTSD group (p=0.01), showing that the association 
between IBS or FD and PTSD was not significant. Further, calculating the PTSD 
Checklist scores to determine PTSD severity it was found that the severity of PTSD 
scores between T1 and T4 correlated only with a diagnosis of GERD and not with either 
IBS or functional dyspepsia. Further detailed analysis of different PTSD symptoms 
subtypes, we determined that a diagnosis of PTSD with re-experiencing symptoms was 
more likely to be accompanied by a diagnosis of IBS compared to other symptom 
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clusters. Looking at extraintestinal comorbidities, depression, anxiety, and fibromyalgia, 























PTSD among veterans is a profound clinical problem with a very high estimated 
prevalence at around 30%. The diagnosis of PTSD carries a high health care burden 
because it leads to a steep decrease in quality of life not only from symptoms and 
financial burden placed on the patient, but also through the comorbidities associated with 
PTSD. Previous studies have identified various psychological comorbidities, such as 
depression and generalized anxiety disorder, and gastrointestinal disorders, such as IBS, 
GERD, and dyspepsia. This study was designed to examine associations between various 
gastrointestinal comorbidities, including IBS, FD, and GERD in a well characterized 
population of combat exposed veterans with PTSD enrolled in the longitudinal 
prospective VALOR cohort. One of the long-term goals of this approach is to provide 
physicians the necessary knowledge to recognize the impact of comorbid GI disorders on 
the natural history of PTSD and afford veterans with GI comorbidities a comprehensive 
medical management to reduce or even resolve GI symptoms. Gastrointestinal disorders 
like IBS, FD, and GERD can place immense burden on the patient not only through 
health care utilization, but the stress of the symptoms which could exacerbate comorbid 
PTSD. By studying associations between PTSD and common gastrointestinal disorders 
more could be learned about the pathology of both diseases. By continuing to research 
these connections we predict that the burden of symptom severity of underlying PTSD 
would be eased and increase quality of life of these veterans.     
 While other studies show the rates of IBS being comorbid with PTSD at around 
36%, the VALOR cohort had a much lower comorbidity rate of IBS and PTSD of around 
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2-2.5%10. The rates of IBS were also found to be lower compared to previous research; 
the VALOR cohort had ISB rates at around 3.8% while worldwide IBS rates are 
estimated to be at 11%1. Other studies that also use a veteran or active-duty population 
similar to the VALOR cohort found that IBS was associated with PTSD. In White et al. 
study looking into trauma history and its effect on developing IBS, it was concluded that 
development of PTSD lead to a moderate increase in the risk of IBS36. This study was 
unique in that the population studied was entirely composed of females and the effects of 
certain types of trauma was also studied in the development of IBS symptoms. Future 
studies using the VALOR cohort also provides an opportunity to collect data on specific 
traumas experienced to examine if the type of trauma experienced, or possibly how the 
trauma was dealt with could influence both development of PTSD and ISB symptoms. 
VALOR cohort data could also be segregated based on gender in the future to determine 
whether this trend could be replicated. Another study by Goodwin et al. also found that 
among veteran populations both IBS was diagnosed at a higher rate compared to the 
VALOR cohort (33.5%), but also that IBS was associated with PTSD with 51% of 
participants with IBS also had PTSD15. This study included the administration of a 
questionnaire to participants, which allowed for a positive diagnosis of IBS.      
Compared to other studies the VALOR cohort had slightly different demographic 
makeups. In aggregate the VALOR cohort had a higher percentage of Caucasians 
enrolled compared to other studies. The VALOR cohort also has on average a younger 
population compared to similar studies, and a lower percentage of participants in this 
cohort completed school beyond high school compared to other studies. The relatively 
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small number of subjects diagnosed with IBS could be possibly explained the difference 
in the demographic composition of the VALOR cohort. Looking into the racial 
breakdown of for diagnosis of IBS and PTSD, African Americans made up 21% and 17% 
of the IBS and PTSD diagnosis respectively, while Caucasian made up 81% and 73% of 
the IBS and PTSD diagnosis respectively. Other studies have placed the prevalence of 
IBS and PTSD in African American populations as 7.9% and 36.3% respectively, and 
among white populations at 13.1% and 22.5% for IBS and PTSD24,37. So while the rate of 
IBS is lower than other researchers have shown, Caucasians in this VALOR cohort were 
diagnosed with IBS at a higher rate. Since the VALOR study cohort is exclusively 
composed of veterans some of the demographic characteristics is expected to be different 
than in other populations. Future studies could account for this difference in 
demographics by ensuring a more even distribution of demographic data, like race, to see 
if diagnosis of IBS and FD align with other studies studying similar populations. 
The only gastrointestinal comorbidity that was found to be associated with PTSD 
in general was GERD, this association between GERD and PTSD was found at the two 
time points that we analyzed (T1 and T4) of the VALOR cohort study. A diagnosis of 
GERD was also associated with an increase in symptom severity for veterans also 
diagnosed with PTSD. But diagnosis of certain PTSD symptom subtypes did predict 
association of IBS with PTSD at the beginning of the study, only the re-experiencing 
symptom subtype of PTSD was more likely to predict an outcome of a future IBS 
diagnosis. These results did change over the course of the study, by the end of the study 
the avoidance symptom subtype and not the re-experiencing subtype predicted IBS. This 
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subtype also only predicted IBS and no other gastrointestinal disorder. Future studies 
could try and explore whether specific subtypes of gastrointestinal disorders are 
associated with psychiatric disorders at higher rates. The different subtypes of IBS affect 
the body differently and could have different effects of the connection between the 
central nervous system and the enteric nervous system. Goodwin et al. was able to 
conclude in their study exploring irritable bowel syndrome in the UK military that higher 
instances of diarrhea was associated with a higher chance of developing PTSD later on15. 
Future studies could try and find whether the future development of psychiatric disorders 
is dependent on which subtype of IBS is present, since IBS-C affects the body differently 
from IBS-D.     
While other studies have shown an association between IBS and PTSD, other 
studies have not studied an association between IBS and specific symptom subtypes of 
PTSD10. Other studies have shown that psychiatric comorbidities like depression or 
anxiety are comorbid with both IBS and PTSD14, but the only psychiatric comorbidity 
that predicted a gastrointestinal disorder was depression and this predicted GERD but not 
IBS. The connection between GERD and depression was not a surprise, because 
depression is recognized as a warning sign for future development of GERD4. While the 
association between IBS and psychiatric disorders like depression and anxiety have been 
noted in previous studies, that association was not seen in this study. Other studies have 
placed the association between IBS and anxiety at around 32%10. This discrepancy could 
be explained by the fact that both IBS and anxiety diagnosis were taken from patient 
records using ICD 9/10, if patient were not diagnosed with either anxiety or IBS at the 
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time of the VALOR cohort study an undercount of both disorders could be possible. 
Compared to previous studies exploring comorbidities for PTSD, the association between 
PTSD and anxiety was moderately lower.  
Looking at the cross tabulations between PTSD and the various gastrointestinal 
disorders studied there were clear trends shown between T1 and T4. GERD without 
esophagitis was much more likely to be associated with PTSD at both time points of the 
study. At T1 FD was more likely to be associated with PTSD compared to IBS, but by T4 
IBS was more likely to be associated with PTSD compared to FD. Over the course of the 
study from T1 to T4 with a mean follow up of close to 5 years the rates of the 4 
gastrointestinal disorders studied decreased, along with their association with PTSD. This 
study concluded in the end that GERD was more likely to be associated with PTSD 
compared to IBS or FD, which is a novel finding and was unsuspected based on prior 
research. Both IBS and FD can be categorized as disruptions of communications between 
the central nervous system and the enteric nervous system, which is why psychiatric 
comorbidities like depression and anxiety are common for those two disorders. But 
GERD is not seen as a disruption of communications between the central nervous system 
and the enteric nervous system but is seen as a physiological disruption. One explanation 
for this finding is that the diagnosis of GERD happened most often after the 
manifestation of PTSD symptoms. One of the factors that can cause GERD or can 
exacerbate it is anxiety, a common symptom and comorbidity of PTSD. Future studies 
could explore the time relationship between PTSD and GERD and see if symptoms of 
GERD manifested before or after symptoms of PTSD manifested. GERD was also found 
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to be associated with an increase in symptom severity of PTSD, similarly to the general 
association between GERD and PTSD this could be explained as temporal association. 
Patients with more severe PTSD symptoms could be experiencing more anxiety and 
stress compared to patients with less severe PTSD symptoms which could make them 
more likely to develop symptoms of GERD in the first place. Future studies could 
explore the relationship between symptom severity of both GERD and PTSD to examine 
if increased symptom severity of GERD increased symptoms severity of PTSD or vice 
versa.      
One limitation for this study was that the diagnosis of IBS, FD, and GERD were 
established using ICD 9/10 codes found in medical records of the participants, and not by 
validated symptom assessment of study subjects. The rates of IBS and FD could be 
potentially underrepresented in the VALOR cohort; other studies that explored the 
psychiatric comorbidities of IBS first administered a questionnaire to establish a 
validated diagnosis of IBS or recorded instances of constipation and diarrhea from 
medical records. There were also similar limitations when trying to include other 
psychiatric comorbidities in the study. Inclusion of disorders like depression, anxiety, and 
panic disorders was also accomplished only on the basis ICD 9/10 codes and not by 
questionnaires given to participants as done previously in similar studies. Future studies 
exploring similar populations could administer similar questionnaires in order to avoid 
this limitation and could also obtain data regarding severity levels for different diseases 
which may not be available on patient records.   
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The difference in comorbidity rates and prevalence of gastrointestinal disorders 
could also be explained by the fact that the VALOR cohort is made up of specifically 
combat exposed veterans in which medical data was taken from medical records, while 
other studies were composed of a more general populations or were able to collect 
specific data on gastrointestinal disorders. Future studies should aim to explore different 
populations in this regard, such as a cohort made up of the general population to ensure 
the strength of any future findings and its ability to be applied more generally as opposed 
to only combat exposed veterans. Discrepancies between this study and similar studies 
could also be explained by the fact that diagnosis data was not established by a clinical, 
validated diagnosis but instead pulled from ICD 9/10 codes found on the patient records. 
Overall, this study showed that the prevalence of IBS among the VALOR Cohort 
is much lower compared to previous studies, but it showed an interesting association 
between IBS and specific symptom subtypes of PTSD. Previous studies have not shown 
any particular connection between comorbidities of PTSD and specific symptom 
subtypes of PTSD. What this study was not able to conclude was the nature of this 
association, only that re-experiencing symptoms of PTSD were specifically associate 
with IBS. Future studies could try and quantify this connection to see if specific symptom 
subtype made a patient more likely to develop certain comorbidities, or if the existence of 
a gastrointestinal comorbidity made future development of specific subtype symptoms 
more likely. Future studies could also study whether certain symptom subtypes 
exacerbated comorbid symptoms, for example symptom severity of re-experiencing 
symptoms of PTSD could be correlated with the severity of bowel symptoms in IBS.  
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This study was used as a retrospective demographic study with a prospective, 
longitudinal observation to confirm an association between common gastrointestinal 
disorders and PTSD. This approach in this study to use the data of IBS and PTSD in the 
valor cohort did not result in a clear-cut explanation for the proposed association, 
especially between the re-experiencing symptoms of PTSD and IBS. Future studies could 
explore into possible stool examinations or other gastrointestinal samples from similar 
populations of combat exposed veterans to test whether there is any physical evidence for 
this association.  
While this study was not able to conclude that IBS was strongly correlated with 
PTSD, the correlation between GERD and PTSD is an entirely novel finding while 
unexpected and surprising since no straightforward pathophysiological relation exist. One 
tantalizing hypothesis could ascribe acid or non-acid mediated neuronal excitation of the 
distal esophagus linking to the activation of the brain gut axis via the vagal afferent 
fibers. Further exploring the connections between these disorders could potentially enable 
physicians to develop more effective care plans that take into account patient’s health in a 
more holistic approach. GERD can lead to many serious health problems such as upper 
GI bleed, peptic stricture, and involuntary weight loss. Therefore, addressing possible 
GERD alarm symptoms in PTSD patients may result also in improvement of PTSD 
symptoms. Compared to other studies, having a long-term cohort like the VALOR cohort 
allows for unique insights because of its excellent patient characterization and its unique 
long-term longitudinal observation period. Similar studies used to explore associations 
between PTSD and various comorbidities usually collect data and interview patients once 
    
 
41
or have a follow up one to two years later. The VALOR cohort did long term follow ups 
to six years after the initial meeting between researcher and participant. Findings made 
using long term cohorts like this are produce more robust data and can stand up to 
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